TrialInternational journal of clinical oncology2025

Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.

Koji Izutsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.